Stress Urinary Incontinence - Pipeline Insight, 2024

Stress Urinary Incontinence - Pipeline Insight, 2024

DelveInsight’s, “Stress Urinary Incontinence - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Stress Urinary Incontinence pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Stress Urinary Incontinence: Understanding

Stress Urinary Incontinence: Overview

Stress Urinary Incontinence (SUI) is a prevalent and distressing condition characterized by the involuntary leakage of urine during physical activities that increase intra-abdominal pressure, such as coughing, sneezing, or exercising. This condition primarily affects women, with factors such as childbirth, menopause, and pelvic floor muscle weakness contributing to its development. SUI significantly impacts quality of life, leading to embarrassment, social withdrawal, and decreased self-esteem.

The pathophysiology of Stress Urinary Incontinence (SUI) is multifactorial and involves various anatomical, physiological, and functional deficits. The primary causes include bladder neck and urethral incompetence, which can be attributed to weakened pelvic floor muscles and urethral sphincter dysfunction. Urethral hypermobility, where the proximal urethra and bladder neck descend and rotate away from the pelvis during increased intra-abdominal pressure, is another significant contributor to SUI. Additionally, impaired urethral support, neuromuscular and mechanical dysfunction of the striated urethral sphincter, are also associated with SUI. These deficits can lead to involuntary urine leakage during physical activities that increase intra-abdominal pressure, such as coughing, sneezing, or exercising. Understanding the underlying pathophysiology is crucial for effective management and treatment of SUI.

Stress Urinary Incontinence (SUI) is characterized by involuntary leakage of urine during physical activities that increase intra-abdominal pressure. The primary symptom is leakage of urine when there is pressure on the bladder, which can occur during various activities such as coughing, sneezing, laughing, exercising, lifting heavy objects, or even standing up from a sitting or lying down position.

The treatment and management of Stress Urinary Incontinence (SUI) involve a range of approaches tailored to the individual's symptoms and needs. Non-surgical therapies include behavioral modifications like bladder training, fluid and dietary adjustments, and pelvic floor muscle training through exercises like Kegels or biofeedback. Pharmacological options, although not uniformly effective, may include medications like anticholinergics, tricyclic antidepressants, and estrogen. Surgical interventions are considered for cases refractory to conservative treatments and may involve procedures to reposition the urethra, create support for the bladder neck, or enhance urethral resistance through slings or injectable. Lifestyle changes such as weight loss, smoking cessation, and dietary modifications can also play a significant role in managing SUI symptoms.

""Stress Urinary Incontinence - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Stress Urinary Incontinence pipeline landscape is provided which includes the disease overview and Stress Urinary Incontinence treatment guidelines. The assessment part of the report embraces, in depth Stress Urinary Incontinence commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Stress Urinary Incontinence collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Stress Urinary Incontinence R&D. The therapies under development are focused on novel approaches to treat/improve Stress Urinary Incontinence.

Stress Urinary Incontinence Emerging Drugs Chapters

This segment of the Stress Urinary Incontinence report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Stress Urinary Incontinence Emerging Drugs

ICES13: Innovacell Biotechnologie GmbH

ICES13 is made from autologous skeletal muscle cells that have been isolated from a muscle biopsy and reproduced in a laboratory. The goal is to treat the cause of the stress urinary incontinence by subsequently injecting ICES13 into the sphincter muscle of the affected person. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with Stress Urinary Incontinence.

VMB-100: Versameb AG

VMB-100 is an intramuscularly locally delivered, sequence engineered messenger ribonucleic acid (mRNA) encoding for human insulin-like growth factor-1 (IGF-1) under investigation for the treatment of stress urinary incontinence (SUI). VMB-100 has the potential to become first-and best-in-class in sustained muscle regeneration following short-term treatment. The drug is currently in the preclinical stage of development for the treatment of patients with Stress Urinary Incontinence.

Further product details are provided in the report……..

Stress Urinary Incontinence: Therapeutic Assessment

This segment of the report provides insights about the different Stress Urinary Incontinence drugs segregated based on following parameters that define the scope of the report, such as:

MajorPlayers in Stress Urinary Incontinence

There are approx. 10+ key companies which are developing the therapies for Stress Urinary Incontinence. The companies which have their Stress Urinary Incontinence drug candidates in the most advanced stage, i.e. Phase III include, Innovacell Biotechnologie GmbH.

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Stress Urinary Incontinence pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous

Subcutaneous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal antibody

Small molecule

Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Stress Urinary Incontinence: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Stress Urinary Incontinence therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Stress Urinary Incontinence drugs.

Stress Urinary Incontinence Report Insights

Stress Urinary Incontinence Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Stress Urinary Incontinence Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Stress Urinary Incontinence drugs?

How many Stress Urinary Incontinence drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Stress Urinary Incontinence?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Stress Urinary Incontinence therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Stress Urinary Incontinence and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Innovacell Biotechnologie GmbH

Versameb AG

Taiho Pharmaceutical

Cook MyoSite

Mapi Pharma

Key Products

ICES13

VMB-100

TAS-303

AMDC-USR (Iltamiocel)

Botulinum toxin